Biologic medications

Dupilumab effective in relieving AD symptoms in children aged six months to six years

Children with eczema between the ages of six months and six years benefit from treatment with dupilumab, according to the results of a...

New monoclonal antibody shows efficacy in CLE

An early study of litifilimab, a humanized monoclonal antibody, has indicated it may be effective in the treatment of cutaneous lupus...

Misuse of alcohol affects response to psoriasis treatment

A study in the British Journal of Dermatology appears to show that alcohol misuse can be associated with poor response to systemic...

Two-year data indicates bimekizumab maintains high levels of psoriatic skin clearance

Study results indicate that maintenance doses of bimekizumab (320 mg) every four or eight weeks can maintain high levels of skin...

Herpes zoster more common in patients with psoriasis, with a higher incidence in those on biologics

A retrospective study from the Taiwan National Health Insurance Research Database of 92,374 patients with psoriasis indicates that those...

Biologics for psoriasis patients may delay or stop progress to psoriatic arthritis

New research from Italy indicates that patients with psoriasis who have been treated with biologic therapies may have a lesser risk of...

HORIZON program provides treatment recommendations for patients with moderate to severe psoriasis

HORIZON program provides recommendations for psoriasis patients with specific joint involvement.

VIDEO: Dupilumab treatment for atopic dermatitis associated with increase ocular disease prevalence

New research has linked dupilumab treatment in atopic dermatitis (AD) patients with an increased prevalence of ocular disease.

1

it's where dermatology lives